Home/Pipeline/CivaSheet®

CivaSheet®

Solid tumors for intraoperative radiation (e.g., Pancreatic, Sarcoma, Breast)

CommercialActive

Key Facts

Indication
Solid tumors for intraoperative radiation (e.g., Pancreatic, Sarcoma, Breast)
Phase
Commercial
Status
Active
Company

About CivaTech Oncology

CivaTech Oncology is a commercial-stage company pioneering a new standard in localized radiation therapy through its proprietary polymer-encapsulated brachytherapy sources. Its flagship products, CivaString® and CivaSheet®, are FDA-cleared and NRC-approved for treating a wide range of solid tumors, offering advantages like homogeneous dose distribution, reduced procedure time, and elimination of long-term metal toxicity risks. Founded in 2009 (with roots from 2006), the company is leveraging its unique technology platform to address unmet needs in cancer care, particularly in complex surgical oncology cases like pancreatic and prostate cancer. It operates as a private entity, generating revenue from the sale of its medical devices.

View full company profile

Therapeutic Areas